Nevertheless, Lu et al. demonstrated, using the CRISPR-Cas9 screening approach, that one of the E2 enzymes’, UBE2G1, protein downregulation, gene deletion or mutation confers resistance to both LEN and POM in human myeloma cell lines and may lead to reduced CRL4 CRBN activity. This evidence concerns the gene CRBN and plasma cell myeloma.